Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VCAM1 | P19320 | 4/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 4/20 | 0.33 |
| ▸ | GRIA1 | P42261 | 2/20 | 0.33 |
| ▸ | GRIA2 | P42262 | 2/20 | 0.33 |
| ▸ | GRIA3 | P42263 | 2/20 | 0.33 |
| ▸ | GRIA4 | P48058 | 2/20 | 0.33 |
| ▸ | GRM6 | O15303 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | APEX1 | P27695 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | TTR | P02766 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4615067 | 0.84 | VCAM1 (0.46) | VCAM1TDP1ATMRAB9ANPC1 | |
| SCHEMBL11882156 | 0.78 | VCAM1 (0.36) | VCAM1TDP1ATMRAB9ANPC1 | |
| SCHEMBL3295789 | 0.77 | MAPT (0.43) | VCAM1TDP1ATMMAPTGRIA1 | |
| SCHEMBL14825528 | 0.77 | VCAM1 (0.47) | VCAM1TDP1ATMRAB9ANPC1 | |
| SCHEMBL25330908 | 0.76 | ATM (0.40) | VCAM1TDP1ATMMAPTGRIA1 | |
| SCHEMBL25330816 | 0.75 | TDP1 (0.41) | VCAM1TDP1MAPTCYP1A2HPGD | |
| SCHEMBL25330793 | 0.70 | TRPV4 (0.32) | EPAS1 | |
| SCHEMBL21624288 | 0.70 | ATM (0.55) | VCAM1TDP1ATMMAPTCYP1A2 | |
| SCHEMBL25329928 | 0.70 | TRPV4 (0.32) | EPAS1 | |
| SCHEMBL30006044 | 0.70 | ATM (0.55) | VCAM1TDP1ATMMAPTCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12528816-B2 | Substituted imidazo [1,2-b] pyridazines and [1, 2, 4] triazolo [ 4,3-b] pyridazines as camkii inhibitors | CARDURION PHARMACEUTICALS, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| US-20240182474-A1 | SUBSTITUTED IMIDAZO [1,2-b] PYRIDAZINES AND [1, 2, 4] TRIAZOLO [ 4,3-b] PYRIDAZINES AS CAMKII INHIBITORS | CARDURION PHARMACEUTICALS, INC. | 2024-06-06 | — | — | US | disclosed |
| US-11795172-B2 | Substituted imidazo[1,2-b]pyridazines and [1,2,4]triazolo[4,3-b]pyridazines as CaMKII inhibitors | CARDURION PHARMACEUTICALS, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| CN-116940354-A | Fused heteroaryl compounds and their use as CaMKII inhibitors | 卡都瑞恩医药股份有限公司 | 2023-10-24 | — | — | CN | disclosed |
| EP-4216948-A1 | FUSED HETEROARYL COMPOUNDS AND THEIR USE AS CAMKII INHIBITORS | Cardurion Pharmaceuticals, Inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| US-20220098207-A1 | FUSED HETEROARYL COMPOUNDS AND THEIR USE AS CAMKII INHIBITORS | CARDURION PHARMACEUTICALS, INC. | 2022-03-31 | — | — | US | disclosed |
| WO-2022067082-A1 | FUSED HETEROARYL COMPOUNDS AND THEIR USE AS CAMKII INHIBITORS | CARDURION PHARMACEUTICALS, LLC (US) | 2022-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12528816-B2 | Substituted imidazo [1,2-b] pyridazines and [1, 2, 4] triazolo [ 4,3-b] pyridazines as camkii inhibitors | RYR2, CACNA1C, CAMK4 | VCAM1 3290/4885TDP1 3747/4885ATM 4434/4885 |
| US-20220098207-A1 | FUSED HETEROARYL COMPOUNDS AND THEIR USE AS CAMKII INHIBITORS | CAMK2B, CAMK2A, CAMK2G | VCAM1 3099/4885TDP1 3202/4885ATM 3854/4885 |
| US-20240182474-A1 | SUBSTITUTED IMIDAZO [1,2-b] PYRIDAZINES AND [1, 2, 4] TRIAZOLO [ 4,3-b] PYRIDAZINES AS CAMKII INHIBITORS | CAMK2B, RYR2, CAMK2A | VCAM1 3472/4885TDP1 2855/4885ATM 4120/4885 |
| US-11795172-B2 | Substituted imidazo[1,2-b]pyridazines and [1,2,4]triazolo[4,3-b]pyridazines as CaMKII inhibitors | CAMK2B, RYR2, CAMK2A | VCAM1 3472/4885TDP1 2855/4885ATM 4120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.